Media coverage
7
Media coverage
Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Morningstar.com Country/Territory United States Date 12/04/19 URL https://www.morningstar.com/news/business-wire/BWIPREM_20190412005455/alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria.html Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Global Banking & Finance Review Country/Territory United Kingdom Date 12/04/19 URL https://www.globalbankingandfinance.com/alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria/ Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 12/04/19 URL https://www.finanznachrichten.de/nachrichten-2019-04/46456760-alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-he-004.htm Persons Manisha Balwani Title ALNYLAM PHARMACEUTICALS : Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet MarketScreener.com Country/Territory United States Date 12/04/19 URL https://www.marketscreener.com/ALNYLAM-PHARMACEUTICALS-8322/news/Alnylam-Pharmaceuticals-Presents-Positive-Complete-Results-from-ENVISION-Phase-3-Study-of-Givosira-28399565/ Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from... Media name/outlet ADVFN Deutschland Country/Territory Germany Date 12/04/19 URL de.advfn.com/p.php?pid=nmona&article=79691320 Persons Manisha Balwani Title Alnylam Pharmaceuticals Inc: Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria (Businesswire) Media name/outlet Avanza Bank AB Country/Territory Sweden Date 12/04/19 URL https://www.avanza.se/placera/pressmeddelanden/2019/04/13/alnylam-pharmaceuticals-inc-alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria.html Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Boerse.de Country/Territory Germany Date 12/04/19 URL https://www.boerse.de/nachrichten/Alnylam-Presents-Positive-Complete-Results-from-ENVISION-Phase-3-Study-of-Givosiran-an-Investigational-RNAi-Therapeutic-for-the-Treatment-of-Acute-Hepatic-Porphyria/8060748 Persons Manisha Balwani